Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

PHASE3CompletedINTERVENTIONAL

Enrollment

900

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2005

Conditions

Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

Interventions

DRUG

R89674 (generic name not yet established)

Trial Locations (6)

Philadelphia

Bel Air

Charlotte

Phoenix

Las Vegas

North Andover

All Listed Sponsors

lead

Vistakon Pharmaceuticals

INDUSTRY

NCT00223951 - Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers | Biotech Hunter | Biotech Hunter